ezetimibe has been researched along with Stroke in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.38) | 29.6817 |
| 2010's | 25 (53.19) | 24.3611 |
| 2020's | 19 (40.43) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, J; Choi, JH; Choi, KH; Choi, SH; Guallar, E; Gwon, HC; Hahn, JY; Kang, D; Kang, M; Kim, J; Lee, JM; Park, H; Park, TK; Song, YB; Yang, JH | 1 |
| Cheng, CY; Hsu, CY; Lee, JD; Lee, M; Ovbiagele, B; Wu, YL | 1 |
| Aertgeerts, B; Bekkering, GET; Delvaux, N; Guyatt, G; Hao, Q; Khan, SU; Li, S; Lone, AN; Riaz, IB; Rodondi, N; Vandvik, PO; Yedlapati, SH | 1 |
| Aertgeerts, B; Agoritsas, T; Al Ansary, L; Assendelft, WJJ; Bekkering, GE; Dawson, A; Delvaux, N; Guyatt, G; Hao, Q; Heen, AF; Jackson, R; Khan, SU; Li, S; Lytvyn, L; Okwen, PM; Ovidiu, MC; Ramaekers, D; Reny, JL; Riaz, IB; Rodondi, N; Siemieniuk, RAC; Spencer, F; Van Driel, M; Vanbrabant, W; Vandvik, PO; Zhao, Q; Zhu, Y | 1 |
| Hackam, DG; Hegele, RA | 1 |
| Catapano, AL; Cosin-Sales, J; Ezhov, MV; Farnier, M; Granados, D; Khan, I; Liu, J; Santoni, S; Santos, RD | 1 |
| Nussbaumerová, B | 1 |
| Sawant, S; Wang, N | 1 |
| Chang, Y; Eom, S; Kim, M; Song, TJ | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Aker, A; Naoum, I; Saliba, W; Zafrir, B | 1 |
| Dearborn-Tomazos, JL; Giugliano, RP; Goldstein, LB; Hirsh, BJ; Peña, JM; Selim, MH; Toth, PP; Woo, D | 1 |
| Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T | 1 |
| Kang, LN; Lan, RF; Wang, L; Xu, B; Xu, W; Zhang, XL; Zhang, XW | 1 |
| Abtan, J; Amarenco, P; Béjot, Y; Bruckert, E; Cabrejo, L; Cha, JK; Charles, H; Ducrocq, G; Giroud, M; Guidoux, C; Hobeanu, C; Kim, JS; Kim, YJ; Labreuche, J; Lapergue, B; Lavallée, PC; Lee, BC; Lee, KB; Leys, D; Mahagne, MH; Meseguer, E; Nighoghossian, N; Pico, F; Samson, Y; Sibon, I; Steg, PG; Sung, SM; Touboul, PJ; Touzé, E; Varenne, O; Vicaut, É; Yelles, N | 1 |
| Ambrosio, G; Armstrong, PW; De Ferrari, GM; Green, JB; Holman, RR; Leonardi, S; Peterson, ED; Stevens, SR; Wamil, M | 1 |
| Amarenco, P; Bruckert, E; Charles, H; Gabriel Steg, P; Giroud, M; Kim, JS; Labreuche, J; Lee, BC; Mahagne, MH; Nighoghossian, N; Vicaut, É | 1 |
| Khan, SA; Naz, A; Qamar Masood, M; Shah, R | 1 |
| Carter, JL; Casas, JP; Hingorani, AD; Overington, JP; Pearce, LS; Schmidt, AF; Wilkins, JT | 1 |
| Azarpazhooh, MR; Bogiatzi, C; Hankey, GJ; Larsson, SC; Spence, JD | 1 |
| Braunwald, E; Cannon, CP; Gencer, B; Giugliano, RP; Im, K; Keech, A; Marston, NA; Sabatine, MS; Sever, P | 1 |
| Baxter, CA; Davies, GM; Vyas, A | 1 |
| Ako, J; Arai, H; Harada-Shiba, M; Hirayama, A; Nakamura, M; Nohara, A; Uno, K | 1 |
| Borghi, C; Del Pinto, R; Ferri, C | 1 |
| Michalopoulou, H; Thomopoulos, C | 1 |
| Bertomeu-González, V; Cordero, A; Rodriguez-Mañero, M | 1 |
| Koh, KK | 1 |
| Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Park, JG; Wiviott, SD | 1 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Bang, LE; Gislason, GH; Høfsten, DE; Jensen, JS; Køber, LV; Pallisgaard, J; Ripa, MS; Schjerning, AM; Theilade, JE; Weeke, PE | 1 |
| Cannon, CP; D'Agostino, RB; Khan, I; Klimchak, AC; Massaro, JM; Reynolds, MR; Sanchez, RJ; Sasiela, WJ | 1 |
| Bang, CN; Boman, K; Dalsgaard, M; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Frikke-Schmidt, R; Lauridsen, BK; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A | 1 |
| Stiefelhagen, P | 1 |
| Erdmann, E | 1 |
| Elkind, MS; Yaghi, S | 1 |
| Acha-Salazar, O; Larrosa-Campo, D; Novo-Robledo, F; Oterino, A; Palacio, E; Revilla, M; Viadero-Cervera, R | 1 |
| De Caterina, R; Marchioli, R; Salvatore, T | 1 |
| Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP | 1 |
| Shi, L; Wang, J; Wang, X; Yang, L; Zhao, J; Zhao, P | 1 |
| Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG | 1 |
| Robinson, JG | 1 |
| Diep, F | 1 |
| Bang, CN; Boman, K; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Nienaber, CA; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Spence, JD | 1 |
| SoRelle, R | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
16 review(s) available for ezetimibe and Stroke
| Article | Year |
|---|---|
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke | 2022 |
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Network Meta-Analysis; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Stroke | 2022 |
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; PCSK9 Inhibitors; Proprotein Convertase 9; Stroke | 2022 |
Lipid-Modifying Therapies and Stroke Prevention.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Lipids; Proprotein Convertase 9; Stroke | 2022 |
Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Stroke | 2023 |
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Secondary Prevention; Stroke | 2023 |
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association.
Topics: American Heart Association; Anticholesteremic Agents; Brain; Cholesterol, LDL; Dementia; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Retrospective Studies; Stroke | 2023 |
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Myocardial Revascularization; Stroke; Treatment Outcome | 2019 |
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Anticholesteremic Agents; Apolipoproteins B; Aspartate Aminotransferases; Bilirubin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injection Site Reaction; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; RNA, Small Interfering; Stroke | 2020 |
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cholinergic Antagonists; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Primary Prevention; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2020 |
Stroke Prevention in Older Adults: Recent Advances.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Carotid Stenosis; Dementia; Diet; Diet, Vegetarian; Endarterectomy, Carotid; Ezetimibe; Factor Xa Inhibitors; Gastrointestinal Microbiome; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Patient Care Planning; Patient Selection; Platelet Aggregation Inhibitors; Renal Insufficiency; Stents; Stroke; Vascular Stiffness; Vitamin B Complex | 2020 |
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Stroke; Treatment Outcome | 2020 |
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
Lipids and Cerebrovascular Disease: Research and Practice.
Topics: Brain Ischemia; Cerebral Hemorrhage; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukoencephalopathies; Lipoprotein(a); Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; Stroke; Triglycerides | 2015 |
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States | 2016 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
9 trial(s) available for ezetimibe and Stroke
| Article | Year |
|---|---|
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke | 2019 |
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2020 |
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Reference Values; Sitagliptin Phosphate; Stroke | 2020 |
Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke.
Topics: Aged; Anticholesteremic Agents; Brain Ischemia; Cholesterol, LDL; Drug Delivery Systems; Ezetimibe; Female; Humans; Male; Middle Aged; Stroke; Time Factors | 2020 |
[Even lower values are even better!].
Topics: Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin; Stroke | 2015 |
[What is the use of even lower LDL cholesterol by combination therapy? A critical viewpoint].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Comorbidity; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prevalence; Risk Factors; Stroke; Survival Rate; Treatment Outcome | 2015 |
Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Anticoagulants; Cholesterol; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Imaging, Three-Dimensional; Interleukin-6; Male; Matrix Metalloproteinase 9; Middle Aged; Retrospective Studies; Stroke; Treatment Outcome; Ultrasonography | 2016 |
Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Atrial Fibrillation; Azetidines; Double-Blind Method; Ezetimibe; Female; Heart Ventricles; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Simvastatin; Stroke; Time Factors; Ultrasonography | 2012 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
22 other study(ies) available for ezetimibe and Stroke
| Article | Year |
|---|---|
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries.
Topics: Brain Ischemia; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2022 |
Hypertension and dyslipidemia treament in stroke.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Brain Ischemia; Calcium Channel Blockers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indapamide; Stroke | 2022 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Delivery of Health Care; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Stroke | 2023 |
Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Fees, Pharmaceutical; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Stroke; United States | 2017 |
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Ezetimibe; Fibric Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Incidence; Ischemic Attack, Transient; Japan; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Observational Studies as Topic; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Prospective Studies; Registries; Research Design; Risk Factors; Stroke | 2017 |
Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Denmark; Diabetes Mellitus; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; PCSK9 Inhibitors; Practice Patterns, Physicians'; Stroke | 2019 |
Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
Topics: Aged; Angina, Unstable; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cause of Death; Cholesterol, LDL; Cohort Studies; Elective Surgical Procedures; Ezetimibe; Female; Hospitalization; Humans; Hypolipidemic Agents; Insurance, Health, Reimbursement; Male; Medication Adherence; Middle Aged; Monte Carlo Method; Myocardial Infarction; Percutaneous Coronary Intervention; Proportional Hazards Models; Risk; Stroke | 2019 |
Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Comorbidity; Coronary Artery Bypass; Ezetimibe; Female; Heart Valve Prosthesis Implantation; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Stroke | 2014 |
Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.
Topics: Aged; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Gallstones; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemia; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Myocardial Infarction; Risk Factors; Stroke | 2015 |
[Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack].
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Retrospective Studies; Stroke | 2016 |
Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT.
Topics: Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proportional Hazards Models; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2016 |
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections | 2016 |
Cholesterol conundrum.
Topics: Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Risk Factors; Stroke | 2011 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |